Arcreal, a Korean AI healthcare company, has secured $5.4 million (8 billion KRW) in Pre-Series A funding from DSC Investment, SDB Investment, Schmidt, and Soo Investment Capital. This brings Arcreal’s cumulative funding to $9.6 million (14.1 billion KRW), with its proprietary technology and global expansion potential recognized by investors.

Since the seed stage, Arcreal has focused on research and development to successfully implement an intraoral scanner using its own technology, known as one of the highest technical barriers in the dental field. The company’s self-developed product “arcscan” has achieved performance comparable to premium products dominated by global major brands, while featuring a proprietary technology design that provides price competitiveness. The company has obtained key medical device approvals including U.S. FDA and European CE MDR, establishing a foundation for global commercialization. Starting late this year, the company plans to accelerate sales by expanding global sales contracts.

Intraoral scanners are core equipment in the dental AI era, capable of directly acquiring precise 3D oral data from patients. Since most dental AI services—including AI diagnosis, CAD design, treatment planning, and prosthetic fabrication—originate from this data, the prevailing forecast in the global market is that intraoral scanner companies will take the lead in dental AI platform competition. Major global dental companies are actively acquiring intraoral scanners and integrated platforms in preparation for AI transformation, securing ecosystem leadership.

Arcreal is one of the few companies with a full-stack structure that directly develops all areas from software engines, AI models, and platforms to hardware design and manufacturing. CEO Seunghyun Jeon, a graduate of Seoul Science High School and Seoul National University, and CTO Kyungguk Kim, who has developed real-time 3D engines in the gaming industry, lead the high-level technology development. KAIST AI Graduate School Chair Professor Jinwoo Shin oversees AI research, further strengthening technological competitiveness.

Professor Shin stated: “Arcreal has established a foundation to directly secure the most precise 3D oral data globally. Based on this, we are accelerating the completion of a 3D vision foundation model specialized in oral structures that understands complex anatomical information such as teeth, gums, and occlusion. Once the model is complete, the dental field will expand beyond automation to personalized patient treatment and predictive medicine, and Arcreal will lead that transformation.”

Junghoon Kim, executive director at SDB Investment, commented: “We have highly valued the Arcreal team’s technology and execution capabilities since the seed stage. The continued participation of existing investors clearly demonstrates that trust. Arcreal is a team that will lead innovation in the global market, starting with intraoral scanners, the first gateway to digital dentistry.”

Based on this investment, Arcreal plans to accelerate AI model advancement and establish a U.S. subsidiary next year to fully launch global business expansion centered on the United States and Europe.